Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pan-tumor × Capecitabine × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 65 Colorectal Neoplasms 39 Rectal Neoplasms 33 Stomach Neoplasms 32 Triple Negative Breast Neoplasms 24 Neoplasm Metastasis 19 Esophageal Neoplasms 15 Colonic Neoplasms 15 Neoplasms 13 Pancreatic Neoplasms 10 Nasopharyngeal Carcinoma 10 Cholangiocarcinoma 10 Adenocarcinoma 10 Biliary Tract Neoplasms 9 Adenocarcinoma Of Esophagus 9 Recurrence 7 Parkinson Disease 4, Autosomal Dominant Lewy Body 7 Locally Advanced Rectal Cancer 7 Brain Neoplasms 7 Anus Neoplasms 6 Neuroendocrine Tumors 5 Gallbladder Neoplasms 5 HER2-positive Breast Cancer 4 Gastrointestinal Neoplasms 4 Esophageal Squamous Cell Carcinoma 4 Colorectal Cancer Metastatic 4 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Pathologic Complete Response 3 Ovarian Neoplasms 3

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡